ON
← Back to feed
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
United States🏛️ PoliticsCenteryesterday

STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

The article discusses recent developments in biotechnology, including Roivant's approval of an autoimmune drug, Cytokinics' release of full data on a heart condition treatment, and ongoing controversies involving former Stanford president Marc Tessier-Lavigne. It also mentions the death of artist Yayoi Kusama and notes that the article is an exclusive story available to STAT+ subscribers.

1 reports

STAT News logoSTAT NewsIndependentCenteryesterday
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching

The article discusses recent developments in biotechnology, including Roivant's approval of an autoimmune drug, Cytokinics' release of full data on a heart condition treatment, and ongoing controversies involving former Stanford president Marc Tessier-Lavigne. It also mentions the death of artist Yayoi Kusama and notes that the article is an exclusive story available to STAT+ subscribers.

Bias read (Center): The article primarily reports on biotech developments and does not take a clear ideological stance. While it mentions political figures and institutions (e.g., the European Society of Cardiology, Stanford), these references are contextual rather than framed with overt bias. The focus remains on biot

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories